Myriad Genetics, Inc. (MYGN)
Analyzes DNA to predict cancer risk and guide personalized cancer treatment decisions.
$5.32-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+36.1%
The outlook
MYGN is trading near the lower end of its 52-week range at $5.32, with analysts holding a neutral stance and a consensus "Hold" rating. The average price target sits roughly 17% above the current price, though the stock is mixed relative to its moving averages. Overall sentiment remains balanced with no strong directional conviction from the market.
What’s behind the score
Analyst consensusHold — 3.0 avg of 8 analysts
Price trendMixed vs its moving averages
52-week range35% of the way from its 52-week low to high
Price targetAvg target +17% vs current price
Analyst price target
~12-month · 8 analysts$6.25average target+17.5% vs now
Now $5.32
Low $4.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$502.5M
52-wk high
$8.59
52-wk low
$3.53
50-day avg
$4.95
200-day avg
$5.65
Trailing P/E
—